Skip to main content

Table 3 Everolimus blood concentration at the time of discontinuation or dose reduction by adverse events

From: Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

Patient number Number of measurements Everolimus blood concentration,
Mean ± SD (ng/mL)
Discontinuation or dose reduction by adverse events
Discontinuation or dose reduction Date (day) Everolimus blood concentration (ng/mL) Adverse events
Pat.1 22 11.2 ± 4.6     
Pat.2 9 16.4 ± 6.2 Discontinuation 147 17.5 AST (G2), ALT (G2), ALP (G2), Hyperglycemia (G2), Mucosal inflammation (G2), Fatigue (G2),
Pneumonitis (G1), Diarrhea (G1), Leukopenia (G1), Neutropenia (G1)
Pat.3 2 13.1 ± 0.6 Discontinuation 26 12.5 Pneumonitis (G3), Mucosal inflammation (G2)
Pat.4 4 27.9 ± 18.0 Dose reduction 15 58.4 Hyperglycemia (G3), Hypoalbuminemia (G3), γ-GTP (G3), AST (G2), ALP (G2), ALP (G1)
Discontinuation 41 19.1 AST (G1), ALT(G1), ALP(G1)
Pat.5 15 8.4 ± 2.5     
Pat.6 3 10.2 ± 0.6     
Pat.7 12 18.8 ± 4.8 Discontinuation 265 20.4 Leukopenia (G3), Thrombocytopenia (G2)
Pat.8 3 8.2 ± 0.5     
Pat.9 4 27.6 ± 4.9 Discontinuation 98 35.4 Pneumonitis (G3), Mucosal inflammation (G2)
Pat.10 5 18.7 ± 1.3 Dose reduction 16 17.1 Mucosal inflammation (G2), ALP (G1), Nausea (G1), Vomiting (G1)
Discontinuation 93 19.5 ALP (G1), Nausea (G1)
  1. AST: Increased aspartate aminotransferase, ALT: Increased alanine transaminase, ALP: Increased alkaline phosphatase, γ-GTP: Increased γ-glutamyltransferase